Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 2021 (LINC02021, also known as LOC124906285) is classified as a long intergenic non-coding RNA (lincRNA), which are autonomously transcribed RNA molecules longer than 200 nucleotides that do not overlap protein-coding genes. LincRNAs are a subclass of long non-coding RNAs and are involved in a variety of mechanisms regulating gene expression, often with tissue specificity, including chromatin remodeling, acting as scaffolds for protein complexes, and contributing to transcriptional regulation. The overwhelming majority of lincRNAs, including LINC02021, have not been functionally annotated or associated with any specific biological pathways, disease mechanisms, or therapeutic targeting; only a small subset of lincRNAs have experimentally confirmed functions or disease associations. There is no evidence that LINC02021 functions as a receptor, enzyme, or other conventional therapeutic target. [1][5][7]
None established for drugs; general mechanisms for lincRNAs include serving as scaffolds for chromatin modifiers, acting as miRNA decoys, and influencing transcription
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 2021 (LINC02021).